Homocysteine and hypertension in diabetes: Does PPAR have a regulatory role?

PPAR Research

Volumn , Issue , 2010, Pages

  Sen, Utpal ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; CIGLITAZONE; COLLAGEN; GLITAZONE DERIVATIVE; HOMOCYSTEINE; HOMOCYSTEINE LOWERING AGENT; HYDROGEN SULFIDE; MATRIX METALLOPROTEINASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIASTOLIC DYSFUNCTION; ENDOTHELIUM CELL; GLOMERULOSCLEROSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; MORBIDITY; MORTALITY; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

EID: 77955391743     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2010/806538     Document Type: Review

References (113)

1. Michalik L., Wahli W., Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions Current Opinion in Biotechnology 1999 10 6 564 570
2. Lee S., Kim W., Moon S.-O., Sung M. J., Kim D. H., Kang K. P., Jang Y. B., Lee J. E., Jang K. Y., Park S. K., Rosiglitazone ameliorates cisplatin-induced renal injury in mice Nephrology Dialysis Transplantation 2006 21 8 2096 2105
3. Michalik L., Auwerx J., Berger J. P., Chatterjee V. K., Glass C. K., Gonzalez F. J., Grimaldi P. A., Kadowaki T., Lazar M. A., O'Rahilly S., Palmer C. N. A., Plutzky J., Reddy J. K., Spiegelman B. M., Staels B., Wahli W., International union of pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacological Reviews 2006 58 4 726 741
4. Matsumoto T., Kobayashi T., Kamata K., Relationships among ET-1, PPAR, oxidative stress and endothelial dysfunction in diabetic animals Journal of Smooth Muscle Research 2008 44 2 41 55
5. Towfighi A., Ovbiagele B., Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers: potential multipronged strategy in stroke prevention Cerebrovascular Diseases 2008 26 2 106 112
6. Berger J., Moller D. E., The mechanisms of action of PPARs Annual Review of Medicine 2002 53 409 435
7. Chen R., Liang F., Moriya J., Yamakawa J.-I., Takahashi T., Shen L., Kanda T., Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? International Journal of Cardiology 2008 130 2 131 139
8. Ruan X., Zheng F., Guan Y., PPARs and the kidney in metabolic syndrome American Journal of Physiology 2008 294 5 F1032 F1047
9. Marx N., Sukhova G. K., Collins T., Libby P., Plutzky J., PPAR activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells Circulation 1999 99 24 3125 3131
10. Takata Y., Liu J., Yin F., Collins A. R., Lyon C. J., Lee C.-H., Atkins A. R., Downes M., Barish G. D., Evans R. M., Hsueh W. A., Tangirala R. K., PPAR -mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 2008 105 11 4277 4282
11. Duan S. Z., Usher M. G., Mortensen R. M., PPARs: the vasculature, inflammation and hypertension Current Opinion in Nephrology and Hypertension 2009 18 2 128 133
12. Hoogeveen E. K., Kostense P. J., Jakobs C., Dekker J. M., Nijpels G., Heine R. J., Bouter L. M., Stehouwer C. D. A., Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn study Circulation 2000 101 13 1506 1511
13. Rodriguez W. E., Joshua I. G., Falcone J. C., Tyagi S. C., Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced type 2 diabetes mellitus American Journal of Physiology 2006 291 1 H81 H87
14. Burrows N. R., Li Y., Geiss L. S., Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline Diabetes Care 2010 33 1 73 77
15. Zelmanovitz T., Gerchman F., Balthazar A. P., Thomazelli F. C., Matos J. D., Canani L. H., Diabetic nephropathy Diabetology Metabolic Syndrome 2009 1 1 10
16. Christensen P. K., Hansen H. P., Parving H.-H., Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients Kidney International 1997 52 5 1369 1374
17. Giunti S., Barit D., Cooper M. E., Mechanisms of diabetic nephropathy: role of hypertension Hypertension 2006 48 4 519 526
18. Cortes P., Zhao X., Riser B. L., Narins R. G., Regulation of glomerular volume in normal and partially nephrectomized rats American Journal of Physiology 1996 270 2 F356 F370
19. Cortes P., Riser B. L., Yee J., Narins R. G., Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications Nephrology Dialysis Transplantation 1999 14 6 1351 1354
20. Endlich N., Endlich K., Stretch, tension and adhesionadaptive mechanisms of the actin cytoskeleton in podocytes European Journal of Cell Biology 2006 85 3-4 229 234
21. Yasuda T., Kondo S., Homma T., Harris R. C., Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells Journal of Clinical Investigation 1996 98 9 1991 2000
22. Riser B. L., Cortes P., Heilig C., Grondin J., Ladson-Wofford S., Patterson D., Narins R. G., Cyclic stretching force selectively up-regulates transforming growth factor- isoforms in cultured rat mesangial cells American Journal of Pathology 1996 148 6 1915 1923
23. Gruden G., Setti G., Hayward A., Sugden D., Duggan S., Burt D., Buckingham R. E., Gnudi L., Viberti G., Mechanical stretch induces monocyte chemoattractant activity via an NF- B-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone Journal of the American Society of Nephrology 2005 16 3 688 696
24. Riser B. L., Varani J., Cortes P., Yee J., Dame M., Sharba A. K., Cyclic stretching of mesangial cells up-regulates intercellular adhesion molecule-1 and leukocyte adherence: a possible new mechanism for glomerulosclerosis American Journal of Pathology 2001 158 1 11 17
25. Sen U., Rodriguez W. E., Tyagi N., Kumar M., Kundu S., Tyagi S. C., Ciglitazone, a PPAR agonist, ameliorates diabetic nephropathy in part through homocysteine clearance American Journal of Physiology 2008 295 5 E1205 E1212
26. Soedamah-Muthu S. S., Chaturvedi N., Teerlink T., Idzior-Walus B., Fuller J. H., Stehouwer C. D. A., Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study Journal of Internal Medicine 2005 258 5 450 459
27. Graham L. M., Daly L. E., Refsum H. M., Robinson K., Brattstrm L. E., Ueland P. M., Palma-Reis R. J., Boers G. H. J., Sheahan R. G., Lsraelsson B., Uiterwaal C. S., Meleady R., McMaster D., Verhoef P., Witteman J., Rubba P., Bellet H., Wautrecht J. C., De Valk H. W., Sales Lis A. C., Parrot-Roulaud F. M., Tan K. S., Higgins I., Garcon D., Medrano M. J., Candito M., Evans A. E., Andria G., Plasma homocysteine as a risk factor for vascular disease: the European concerted action project Journal of the American Medical Association 1997 277 22 1775 1781
28. Sundstrm J., Sullivan L., D'Agostino R. B., Jacques P. F., Selhub J., Rosenberg I. H., Wilson P. W. F., Levy D., Vasan R. S., Plasma homocysteine, hypertension incidence, and blood pressure tracking: the framingham heart study Hypertension 2003 42 6 1100 1105 (Pubitemid 37549062)
29. van Guldener C., Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering? Nephrology Dialysis Transplantation 2006 21 5 1161 1166
30. Wollesen F., Brattstrm L., Refsum H., Ueland P. M., Berglund L., Berne C., Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus Kidney International 1999 55 3 1028 1035
31. Veldman B. A. J., Vervoort G., Blom H., Smits P., Reduced plasma total homocysteine concentrations in type 1 diabetes mellitus is determined by increased renal clearance Diabetic Medicine 2005 22 3 301 305
32. Ninomiya T., Kiyohara Y., Kubo M., Tanizaki Y., Tanaka K., Okubo K., Nakamura H., Hata J., Oishi Y., Kato I., Hirakata H., Iida M., Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study American Journal of Kidney Diseases 2004 44 3 437 445
33. Friedman A. N., Bostom A. G., Selhub J., Levey A. S., Rosenberg I. H., The kidney and homocysteine metabolism Journal of the American Society of Nephrology 2001 12 10 2181 2189
34. Finkelstein J. D., Methionine metabolism in mammals Journal of Nutritional Biochemistry 1990 1 5 228 237
35. House J. D., Brosnan M. E., Brosnan J. T., Renal uptake and excretion of homocysteine in rats with acute hyperhomocysteinemia Kidney International 1998 54 5 1601 1607
36. House J. D., Brosnan M. E., Brosnan J. T., Characterization of homocysteine metabolism in the rat kidney Biochemical Journal 1997 328 1 287 292
37. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease American Journal of Kidney Diseases 1998 32 5 S112 S119
38. van Guldener C., Kulik W., Berger R., Dijkstra D. A., Jakobs C., Reijngoud D.-J., Donker A. J. M., Stehouwer C. D. A., De Meer K., Homocysteine and methionine metabolism in ESRD: a stable isotope study Kidney International 1999 56 3 1064 1071
39. Stam F., van Guldener C., ter Wee P. M., Kulik W., Smith D. E. C., Jakobs C., Stehouwer C. D. A., De Meer K., Homocysteine clearance and methylation flux rates in health and end-stage renal disease: association with S-adenosylhomocysteine American Journal of Physiology 2004 287 2 F215 F223
40. Stam F., van Guldener C., Ter Wee P. M., Jakobs C., de Meer K., Stehouwer C. D. A., Effect of folic acid on methionine and homocysteine metabolism in end-stage renal disease Kidney International 2005 67 1 259 264
41. Vermeulen E. G. J., Niessen H. W. M., Bogels M., Stehouwer C. D. A., Rauwerda J. A., van Hinsbergh V. W. M., Decreased smooth muscle cell/extracellular matrix ratio of media of femoral artery in patients with atherosclerosis and hyperhomocysteinemia Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 4 573 577
42. Stehouwer C. D. A., van Guldener C., Does homocysteine cause hypertension? Clinical Chemistry and Laboratory Medicine 2003 41 11 1408 1411
43. van Guldener C., Nanayakkara P. W. B., Stehouwer C. D. A., Homocysteine and blood pressure Current Hypertension Reports 2003 5 1 26 31
44. Locatelli F., Canaud B., Eckardt K.-U., Stenvinkel P., Wanner C., Zoccali C., The importance of diabetic nephropathy in current nephrological practice Nephrology Dialysis Transplantation 2003 18 9 1716 1725
45. Aronson D., Hyperglycemia and the pathobiology of diabetic complications Advances in Cardiology 2008 45 1 16
46. Lu T.-C., Wang Z.-H., Feng X., Chuang P. Y., Fang W., Shen Y., Levy D. E., Xiong H., Chen N., He J. C., Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy Kidney International 2009 76 1 63 71
47. Toyoda M., Najafian B., Kim Y., Caramori M. L., Mauer M., Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy Diabetes 2007 56 8 2155 2160
48. Zheng F., Fornoni A., Elliot S. J., Guan Y., Breyer M. D., Striker L. J., Striker G. E., Upregulation of type I collagen by TGF- in mesangial cells is blocked by PPAR activation American Journal of Physiology 2002 282 4 F639 F648
49. Ohashi R., Kitamura H., Yamanaka N., Peritubular capillary injury during the progression of experimental glomerulonephritis in rats Journal of the American Society of Nephrology 2000 11 1 47 56
50. Shimizu A., Kitamura H., Masuda Y., Ishizaki M., Sugisaki Y., Yamanaka N., Rare glomerular capillary regeneration and subsequent capillary regression with endothelial cell apoptosis in progressive glomerulonephritis American Journal of Pathology 1997 151 5 1231 1239
51. Yang H.-C., Ma L.-J., Ma J., Fogo A. B., Peroxisome proliferator- activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis Kidney International 2006 69 10 1756 1764
52. Calkin A. C., Giunti S., Jandeleit-Dahm K. A., Allen T. J., Cooper M. E., Thomas M. C., PPAR- and- agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrology Dialysis Transplantation 2006 21 9 2399 2405
53. Balakumar P., Rose M., Ganti S. S., Krishan P., Singh M., PPAR dual agonists: are they opening Pandora's box? Pharmacological Research 2007 56 2 91 98
54. Izzedine H., Launay-Vacher V., Buhaescu I., Heurtier A., Baumelou A., Deray G., PPAR -agonists' renal effects Minerva Urologica e Nefrologica 2005 57 4 247 260
55. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H., Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF- B activation American Journal of Physiology 2007 292 4 F1141 F1150
56. Ko G. J., Kang Y. S., Han S. Y., Lee M. H., Song H. K., Han K. H., Kim H. K., Han J. Y., Cha D. R., Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats Nephrology Dialysis Transplantation 2008 23 9 2750 2760
57. Rodriguez W. E., Tyagi N., Joshua I. G., Passmore J. C., Fleming J. T., Falcone J. C., Tyagi S. C., Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus American Journal of Physiology 2006 291 3 F694 F701
58. Makita Y., Moczulski D. K., Bochenski J., Smiles A. M., Warram J. H., Krolewski A. S., Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes American Journal of Kidney Diseases 2003 41 6 1189 1194
59. Vaccaro O., Perna A. F., Mancini F. P., Iovine C., Cuomo V., Sacco M., Tufano A., Rivellese A. A., Ingrosso D., Riccardi G., Plasma homocysteine and microvascular complications in type 1 diabetes Nutrition, Metabolism and Cardiovascular Diseases 2000 10 6 297 304
60. Tyagi S. C., Smiley L. M., Mujumdar V. S., Clonts B., Parker J. L., Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone Molecular and Cellular Biochemistry 1998 181 1-2 107 116
61. Bissonnette R., Treacy E., Rozen R., Boucher B., Cohn J. S., Genest J. Jr., Fenofibrate raises plasma homocysteine levels in the fasted and fed states Atherosclerosis 2001 155 2 455 462
62. Lee K.-M., Tsai K. Y., Wang N., Ingber D. E., Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility American Journal of Physiology 1998 274 1 H76 H82
63. Camp T. M., Smiley L. M., Hayden M. R., Tyagi S. C., Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats Journal of Hypertension 2003 21 9 1719 1727
64. Kagan R. A., Kinsel M., Gloor K., Mylniczenko N. D., Langan J. N., Farina L. L., Terio K. A., Morphologic evidence suggestive of hypertension in western gray kangaroos (Macropus fuliginosus) Veterinary Pathology 2009 46 5 977 984
65. Rysz J., Banach M., Stolarek R. A., Pasnik J., Cialkowska-Rysz A., Koktysz R., Piechota M., Baj Z., Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy Journal of Nephrology 2007 20 4 444 452
66. Endo T., Nakabayashi K., Sekiuchi M., Kuroda T., Soejima A., Yamada A., Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining Clinical and Experimental Nephrology 2006 10 4 253 261
67. Hirahara I., Inoue M., Okuda K., Ando Y., Muto S., Kusano E., The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysisa multicentre study in Japan Nephrology Dialysis Transplantation 2007 22 2 560 567
68. Chang H.-R., Yang S.-F., Li M.-L., Lin C.-C., Hsieh Y.-S., Lian J.-D., Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease Clinica Chimica Acta 2006 366 1-2 243 248
69. Zaouio P., Cantin J. F., Alimardani-Bessette M., Monier F., Halimi S., Morel F., Cordonnier D., Role of metalloproteases and inhibitors in the occurrence and progression of diabetic renal lesions Diabetes and Metabolism 2000 26 supplement 4 25 29
70. Eddy A. A., Kim H., Lopez-Guisa J., Oda T., Soloway P. D., McCulloch L., Liu E., Wing D., Interstitial fibrosis in mice with overload proteinuria: deficiency of TIMP-1 is not protective Kidney International 2000 58 2 618 628
71. Hoppeler H, Kayar S. R., Capillarity and oxidative capacity of muscles News in Physiological Sciences 1988 3 113 116
72. Pinsky D. J., Patton S., Mesaros S., Brovkovych V., Kubaszewski E., Grunfeld S., Malinski T., Mechanical transduction of nitric oxide synthesis in the beating heart Circulation Research 1997 81 3 372 379
73. Rodriguez W. E., Sen U., Tyagi N., Kumar M., Carneal G., Aggrawal D., Newsome J., Tyagi S. C., PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice International Journal of Biological Sciences 2008 4 4 236 244
74. Stehouwer C. D. A., van Guldener C., Does homocysteine cause hypertension? Clinical Chemistry and Laboratory Medicine 2003 41 11 1408 1411
75. Jakubowski H., Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels Journal of Biological Chemistry 1997 272 3 1935 1942
76. Jakubowski H., Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels FASEB Journal 1999 13 15 2277 2283
77. Jakubowski H., The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease Journal of Physiology and Pharmacology 2008 59 supplement 9 155 167
78. Jakubowski H., Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis Journal of Nutrition 2001 131 11 2983S 2987S
79. Jakubowski H., Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease Journal of Biological Chemistry 2002 277 34 30425 30428
80. Gowacki R., Jakubowski H., Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation Journal of Biological Chemistry 2004 279 12 10864 10871
81. Jakubowski H., Boers G. H. J., Strauss K. A., Mutations in cystathionine -synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans FASEB Journal 2008 22 12 4071 4076
82. Pera-Kajn J., Stanger O., uczak M., Zikowska A., Malendowicz L. K., Twardowski T., Lhotak S., Austin R. C., Jakubowski H., Immunohistochemical detection of N-homocysteinylated proteins in humans and mice Biomedicine and Pharmacotherapy 2008 62 7 473 479
83. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J. H., Den Heijer M., Kluijtmans L. A. J., Van den Heuvel L. P., Rozen R., A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase Nature Genetics 1995 10 1 111 113
84. Golledge J., Norman P. E., Relationship between two sequence variations in the gene for peroxisome proliferator-activated receptor-gamma and plasma homocysteine concentration. Health in men study Human Genetics 2008 123 1 35 40
85. Sharma A. M., Staels B., Review: peroxisome proliferator-activated receptor and adipose tissueunderstanding obesity-related changes in regulation of lipid and glucose metabolism Journal of Clinical Endocrinology and Metabolism 2007 92 2 386 395
86. Murthy S. N., Obregon D. F., Chattergoon N. N., Fonseca N. A., Mondal D., Dunne J. B., Diez J. G., Jeter J. R. Jr., Kadowitz P. J., Agrawal K. C., McNamara D. B., Fonseca V. A., Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation, and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet Metabolism 2005 54 5 645 652
87. Sahin M., Tutuncu N. B., Ertugrul D., Tanaci N., Guvener N. D., Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus Journal of Diabetes and Its Complications 2007 21 2 118 123
88. Yang G., Wu L., Jiang B., Yang W., Qi J., Cao K., Meng Q., Mustafa A. K., Mu W., Zhang S., Snyder S. H., Wang R., H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine -lyase Science 2008 322 5901 587 590
89. Wang R., Hydrogen sulfide: a new EDRF Kidney International 2009 76 7 700 704
90. Chang L., Geng B., Yu F., Zhao J., Jiang H., Du J., Tang C., Hydrogen sulfide inhibits myocardial injury induced by homocysteine in rats Amino Acids 2008 34 4 573 585
91. Kimura Y., Kimura H., Hydrogen sulfide protects neurons from oxidative stress FASEB Journal 2004 18 10 1165 1167
92. Yonezawa D., Sekiguchi F., Miyamoto M., Taniguchi E., Honjo M., Masuko T., Nishikawa H., Kawabata A., A protective role of hydrogen sulfide against oxidative stress in rat gastric mucosal epithelium Toxicology 2007 241 1-2 11 18
93. Yan S.-K., Chang T., Wang H., Wu L., Wang R., Meng Q. H., Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells Biochemical and Biophysical Research Communications 2006 351 2 485 491
94. Libby P., Inflammation in atherosclerosis Nature 2002 420 6917 868 874
95. Nava M., Quiroz Y., Vaziri N., Rodrguez-Iturbe B., Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats American Journal of Physiology 2003 284 3 F447 F454
96. Sung F. L., Siow Y. L., Wang G., Lynn E. G., O K., Homocysteine stimulates the expression of monocyte chemoattractant protein-1 in endothelial cells leading to enhanced monocyte chemotaxis Molecular and Cellular Biochemistry 2001 216 1-2 121 128 (Pubitemid 32142232)
97. Wang G., Siow Y. L., O K., Homocysteine stimulates nuclear factor B activity and monocyte chemoattractant protein-1 expression in vascular smooth-muscle cells: a possible role for protein kinase C Biochemical Journal 2000 352 3 817 826
98. Poddar R., Sivasubramanian N., DiBello P. M., Robinson K., Jacobsen D. W., Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells implications for vascular disease Circulation 2001 103 22 2717 2723
99. Wang G., Woo C. W. H., Sung F. L., Siow Y. L., O K., Increased monocyte adhesion to aortic endothelium in rats with hyperhomocysteinemia: role of chemokine and adhesion molecules Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 11 1777 1783
100. Wang G., Siow Y. L., O K., Homocysteine induces monocyte chemoattractant protein-1 expression by activating NF- B in THP-1 macrophages American Journal of Physiology 2001 280 6 H2840 H2847
101. Kerkeni M., Tnani M., Chuniaud L., Miled A., Maaroufi K., Trivin F., Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone Molecular and Cellular Biochemistry 2006 291 1-2 119 126
102. Najib S., Snchez-Margalet V., Homocysteine thiolactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation Journal of Molecular Endocrinology 2005 34 1 119 126
103. owicka E., Betowski J., Hydrogen sulfide (H2S)the third gas of interest for pharmacologists Pharmacological Reports 2007 59 1 4 24
104. Clarke R., Collins R., Lewington S., Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis Journal of the American Medical Association 2002 288 16 2015 2022
105. Den Heijer M., Lewington S., Clarke R., Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies Journal of Thrombosis and Haemostasis 2005 3 2 292 299
106. Marcus J., Sarnak M. J., Menon V., Homocysteine lowering and cardiovascular disease risk: lost in translation Canadian Journal of Cardiology 2007 23 9 707 710
107. Lonn E., Yusuf S., Arnold M. J., Sheridan P., Pogue J., Micks M., McQueen M. J., Probstfield J., Fodor G., Held C., Genest Jr. J., Homocysteine lowering with folic acid and B vitamins in vascular disease The New England Journal of Medicine 2006 354 15 1567 1577
108. Bnaa K. H., Njlstad I., Ueland P. M., Homocysteine lowering and cardiovascular events after acute myocardial infarction The New England Journal of Medicine 2006 354 15 1578 1588
109. den Heijer M., Willems H. P. J., Blom H. J., Gerrits W. B. J., Cattaneo M., Eichinger S., Rosendaal F. R., Bos G. M. J., Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial Blood 2007 109 1 139 144
110. Jamison R. L., Hartigan P., Kaufman J. S., Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial Journal of the American Medical Association 2007 298 10 1163 1170
111. Rodionov R. N., Lentz S. R., The homocysteine paradox Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 6 1031 1033
112. Albert C. M., Cook N. R., Gaziano J. M., Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial The Journal of American Medical Association 2008 299 17 2027 2036
113. Lonn E., Homocysteine-lowering B vitamin therapy in cardiovascular preventionwrong again? The Journal of American Medical Association 2008 299 17 2086 2087